Methods. We used claims data from 4 large national insurers in the FDAsponsored Sentinel Initiative, which was developed to monitor the safety of FDAregulated medical products. With a self-controlled risk interval design, the risk of FS in 0-1 days following IIV and following PCV13 was compared with a comparison interval (14-20 days), adjusting for confounding by age, calendar time, and concomitant vaccination with the other vaccine. In exploratory analyses, we assessed whether the effect of IIV is modified by concomitant administration of PCV13.
Incidence of Invasive Pneumococcal Disease Before and During an Era of Use of Three Different Pneumococcal Conjugate Vaccines in Quebec
Background. In Quebec, 7-valent (PCV7), 10-valent (PCV10) and 13-valent (PCV13) pneumococcal conjugate vaccines were successively used for children immunization according to a 2 + 1 doses schedule.
Objective: To assess the impact of this program on the epidemiology of invasive pneumococcal disease (IPD).
Methods. Notification (2000 Notification ( -2016 and laboratory surveillance (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) ) data were analyzed and the immunization status of IPD cases in 2011-2015 was checked.
Results. In children <5 years, IPD rate decreased from 69/100,000 in 2003 to 12/100,000 in 2016 (83% reduction). Following PCV7 introduction in 2004, there was a rapid decline in incidence of homologous serotypes. 7F cases and 19A decreased following PCV10 introduction in 2009 and PCV13 in 2011, whereas decrease in serotype 3 IPD was minimal. Non-vaccine types IPD increased and represented 79% of cases in 2016. The same pattern was seen in adults but replacement was complete and there was no decrease in overall IPD rate. In those 65 years and over, PCV13 serotypes represented 28% of cases in 2016, and 62% were covered by the 23-valent polysaccharide vaccine. Out of 7 IPD cases caused by serotype 3 in children vaccinated with PCV13, 5 occurred more than one year following the booster dose, which suggests short-term protection. Out of 27 breakthrough 19A cases, 17 occurred between 8 and 14 months of age in children who had received the 2 primary PCV13 doses but not the toddler booster dose, which suggests a window of susceptibility in a 2 + 1 schedule.
Conclusion. Hopefully, 19A incidence in children will continue to decrease and herd protection would eventually close the window of susceptibility. Serotype 3 is fortunately not frequent in children but a hard nut to crack. In elderly adults, PCV13 serotype coverage is diminishing year after year but a majority of cases remains potentially covered by the 23-valent polysaccharide vaccine. Methods. We collected NP swabs from 600 healthy or sick children <5 years old at Boston Medical Center from Nov 2015 -Mar 2016 and used enhanced microbiologic culture and molecular identification strategies to characterize SP colonization. NP specimens were broth enriched for 4 hours and cultured on selective blood agar; routine microbiologic methods were used to isolate and identify SP. A second aliquot of enriched broth was used for DNA isolation. RTPCR assays were performed targeting the lytA, piaB (SP membrane permease), cpsA (SP capsule operon) genes, and 21 SP serotypes: all serotypes included in 13-valent pneumococcal conjugate vaccine and 8 additional non-vaccine serotypes.
Results. In our sample, 16% of specimens were SP positive via culture and 33% were RTPCR-positive (Cq≤35) for the lytA gene. Multiplex RTPCR assays with both the lytA and piaB genes yielded a positive result for 24% of samples. Further RTPCR confirmed that 99% of the lytA/piaB positive samples were positive for cpsA (a second marker for assay validation) but only 70% of the lytA positive, paiB negative samples were cpsA positive. Serogroup 19 was the most frequently isolated vaccine serogroup using both culture and RTPCR; molecular analysis identified 6% of specimens with concurrent carriage of more than one serotype.
Conclusion. Compared with enhanced culture, we found a 50% increase in SP detection using combined lytA and piaB multiplex RTPCR. Similarly, the proportion of children colonized with vaccine serotypes increased from 2% to 7%. This work is funded by an investigator initiated grant to BUMC from Pfizer. 
